Report
Oussema Denguir

Adocia : X Adocia réécrit son avenir

>56 M€ de cash à fin juin - Adocia a publié hier soir ses chiffres au titre du S1 2018, le CA ressort à 32.8 M€ (vs 19.4 au S1 2017) provenant essentiellement de l’accord de partenariat en Chine avec Tonghua Dongbao (50 M$ d’upfront et 85 M$ en milestones) pour BC Lispro et BC Combo. Les charges opérationnelles progressent à 21.78 M€ (+37% yoy) essentiellement du fait des frais juridiques (3.8 M€) engagés dans le cadre de l’arbitrage face à Eli Lilly et 2 M€ d’augmen...
Underlying
Adocia SA

ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch